anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To obtain a microemulsion having fine particle size and improved in stability of a medicinal agent in an aqueous solution by dissolving a high polar oil soluble medicinal agent in a specific oil, adding a predetermined specific emulsifier and blending a predetermined amount of a water soluble polyhydric alcohol under agitation. SOLUTION: This micro emulsion is obtained by formulating (C) a water-soluble polyhydric alcohol to a mixture of (A) a high polar oil soluble medicinal agent and a mixed oil of a high polar oil with a low polar oil with (B) a polyglycerol mono-fatty acid ester under agitation to prepare a gel-like material, which is diluted with water to an O/W type emulsion of fine particles. Here, the amount to be added is brought to 0.3-3 pts.wt. of (B) based on 1 pt.wt. of (A) arid 0.1-3 pts.wt. of (C) based on 1 pt.wt. of (A)+(B). As the high polar oil, triethyl citrate, etc., as the low polar oil, a liquid paraffin, etc., and as the medicinal agent, riboflavin butyrate, etc., are preferable.
Fatigue is defined as any perceived or actual physical or mental tiredness that adversely affects the quality of life \[7,8\]. The multifaceted nature of fatigue means it manifests in various forms, including physical cognitive, and emotional. Fatigue may involve chronic exhaustion and reduced mobility that cannot be relieved by rest \[9,10\]. CRF is associated with cancer progression and treatment, presenting it as a painful, persistent, and subjective sensation involving physical, emotional, and cognitive tiredness or exhaustion. CRF disproportionately affects physical activities and impairs executive functions in daily life \[10,11\]. Factors contributing to CRF include cancer itself, treatment side effects, psychological factors such as personality traits (e.g., levels of optimism, anxiety, or depression), comorbid physical conditions, iatrogenic comorbidities, and lifestyle factors (e.g., physical activity levels) \[10-12\]. From the perspective of individual patients, fatigue frequently coexists with symptom clusters, such as insomnia, low mood or depression, or pain, collectively resulting in reduced daily functioning and diminished quality of life \[13\]. Various non-pharmaceutical interventions have demonstrated effectiveness in addressing CRF, including physical activity, mind-body approaches, and psychosocial interventions \[9,14,15\]. Therefore, this study aims to investigate the level of fatigue among terminal cancer patients receiving home-based hospice care, hospital-based hospice care, and hospice-shared care. The anticipated results may facilitate the enhancement of CRF management strategies
PURPOSE: To obtain the subject preparation having raised sealing efficiency of a physiologically active substance, suppressed leakage at an early stage after administration, keeping the physiologically active substance stably for a long period of time and causing slight loss of the physiologically active substance. CONSTITUTION: This preparation comprises (A) a water-insoluble or a slightly water-soluble polyvalent metal salt of a water-soluble peptide physiologically active substance except endothelin antagonist and (B) a polymer degradable in vivo. The physiologically active substance preferably contains a water-soluble peptide or its derivative, especially a hormone (growth hormone or insulin) cytokinin (interferon) or a growth factor. The polyvalent metal salt is preferably a transition metal salt or a zinc salt and has about 0-0.1 (w/w) water solubility. The preparation contains about 0.1-50wt.% of the salt. The component B is preferably an aliphatic polyester [lactic acid and glycol (composition ratio of 100/0-40060)].
The recommended dose of CYKLOKAPRON is 10 mg/kg actual body weight intravenously administered as a single dose, immediately before tooth extractions Infuse no more than 1 mL/minute to avoid hypotension [see Warnings and Precautions (5.1)]. Following tooth extraction, CYKLOKAPRON may be administered for 2 to 8 days at a dose of 10 mg/kg actual body weight 3 to 4 times daily, intravenously.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

For intravenous infusion, CYKLOKAPRON Injection may be mixed with most solutions for infusion such as electrolyte solutions, carbohydrate solutions, amino acid solutions, and Dextran solutions. Heparin may be added to CYKLOKAPRON Injection. CYKLOKAPRON Injection should NOT be mixed with blood. The drug is a synthetic amino acid and should NOT be mixed with solutions containing penicillin.

Discard any unused portion.

The diluted mixture may be stored for up to 4 hours at room temperature prior to patient administration.
Background and Objectives: Systemic-inflammation-based prognostic scores and hematological indices have shown value in predicting outcomes in various clinical settings. However, their effectiveness in predicting outcomes specifically for IgA nephropathy (IgAN) and membranous nephropathy (MN), the most common primary glomerular diseases diagnosed by kidney biopsy, has not been thoroughly investigated. Materials and Methods: We conducted a retrospective, observational study involving 334 adult patients with biopsy-proven IgAN (196 patients) and MN (138 patients) from January 2008 to December 2017 at a tertiary center. We assessed six prognostic scores [Glasgow prognostic score (GPS), modified GPS (mGPS), prognostic nutritional index (PNI), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-C-reactive protein ratio (LCRP)] and two hematological indices [red blood cell distribution width (RDW), platelet distribution width (PDW)] at diagnosis and examined their relationship with kidney and patient survival. Results: End-stage kidney disease (ESKD) occurred more frequently in the IgAN group compared to the MN group (37% vs. 12%, p = 0.001). The mean kidney survival time was 10.7 years in the IgAN cohort and 13.8 years in the MN cohort. After adjusting for eGFR and proteinuria, lower NLR and higher LCRP were significant risk factors for ESKD in IgAN. In the MN cohort, no systemic-inflammation-based scores or hematological indices were associated with kidney survival. There were 38 deaths (19%) in the IgAN group and 29 deaths (21%) in the MN group, showing no significant difference in mortality rates. The mean survival time was 13.4 years for the IgAN group and 12.7 years for the MN group. In the IgAN group, a lower PLR was associated with a higher mortality after adjusting for age, the Charlson comorbidity score, eGFR, and proteinuria. In patients with MN, higher NLR, PLR, and RDW were associated with increased mortality. Conclusions: NLR and LCRP are significant predictors of ESKD in IgAN, while PLR is linked to increased mortality. In MN, NLR, PLR, and RDW are predictors of mortality but not kidney survival. These findings underscore the need for disease-specific biomarkers and indicate that systemic inflammatory responses play varying roles in the progression and outcomes of these glomerular diseases. Future studies on larger cohorts are necessary to validate these markers.
Critical care nurses need to comply with caring behaviors when caring for postoperative cardiac patients. Furthermore, patient satisfaction is a key indicator of nursing care quality. As such, this study focused on these critical issues considering the limited research available on the impact of caring behaviors on postoperative cardiac patient satisfaction. The study aimed to evaluate the impact of implementing a nurse caring behavior protocol on postoperative cardiac patient satisfaction. The study was conducted at a cardiac surgery intensive care unit of Alexandria Main University Hospital, Egypt. Sixty adults, conscious cardiac surgery patients, were included during the first 2 days following surgery. Patients were randomly assigned to either a control group, which received routine nursing care, or a protocol group, which received nursing care based on nurse care behaviors protocol through a simple randomization method. One tool was used "Postoperative Cardiac Patient Satisfaction with Nurse Caring Behaviors Evaluation Questionnaire". At the end of the second day, patients were asked regarding their satisfaction with the nursing care received based on caring behaviors. These nursing care included intensive care unit admission and orientation processes, physical care, psychological care, and social interaction between patient and nurse, providing health teaching, and maintaining a safe healing environment.
Participants randomized to the mHealth app (Omron Connect) arm will receive reminder messages to check their BP via push notifications from the Omron Connect app at least three times weekly. Upon receipt of the BP reading to the research platform from Omron Connect, participants will receive automatic tailored text message feedback similar to the texting arm. Participants will asked to set a daily step goal of at least 3,000 steps per day and transmit their step count information from their FitBit. Participants will be reminded once a day to sync their FitBit. Motivating messages will be sent weekly. After 4 weeks, and 8 weeks of the study, a usability survey will be sent. Weekly and daily feedback will be sent. At the conclusion of week 6, individuals will "crossover" and will continue for an additional 6 weeks using the opposite technology to communicate BP readings.
Healthier lifestyles, relating to physical activity and diet, reduce the risk of heart disease and stroke. However, making and sustaining lifestyle changes is difficult. More information is needed about effective ways to help people begin to change their lifestyle behaviours. The investigators propose to test the feasibility of using a 'tool' (the SHARED-D questionnaire) in guiding discussions between people and health professionals about physical activity and diet, and support people in making decisions about why and how they might begin to fit more exercise and healthy food into their daily routines. The 'tool' (SHARE-D) consists of questions to help people think about their personal circumstances and their motivation, opportunities, capabilities and priorities, and includes information about heart disease and stroke.

The investigators will explore the use of this tool in general practice, assessing patients' physical activity and diet behaviour after 1 and 3 months. Patients' and healthcare professionals' views of its use and how it influenced decisions will help to improve the tool's design. Participants' opinions regarding its format and method of delivery will inform future plans for its use and the design of a study of its effectiveness in helping people to begin to change their behaviour and achieve healthy lifestyles, hoping to lead to improved quality of life for people with heart disease and stroke.
<P>PROBLEM TO BE SOLVED: To provide a hybridoma cell line producing a monoclonal antibody inhibiting CD14-mediated cell activation.  <P>SOLUTION: A method for inhibiting the CD14-mediated activation of a cell expressing a CD14 receptor includes bringing an effective amount of an antibody or a biologically active fragment thereof into contact with the cell. The antibody binds to a CD14 on the cell surface, and inhibits the CD14-mediated activation by a ligand. Furthermore, the ligand binds to a CD14 of the cell in the presence of the antibody, and stimulates the cell activation in the absence of the antibody. At least 50% of the ligand binds to the cell surface CD14 in the presence of the antibody.  <P>COPYRIGHT: (C)2010,JPO&INPIT
Iron (III) - glycerin - hydroxycarboxylic acid complexes are prepared by mixing in an aqueous medium an iron (III) compound, glycerin and a hydroxycarboxylic acid, and adjusting the pH of the reaction mixture to a value of at least 5. Preferably the pH of the reaction mixture is 5-8 and the mol. ratios of the iron (III) compound: glycerin: hydroxycarboxylic acid are 1: - 10:1/3-3. The iron (III) compound may be ferric chloride, ferric sulphate or an iron (III) hydroxycarboxylic acid salt such as ferric citrate. The hydroxycarboxylic acid reactant may be tartaric acid, citric acid, malic acid or gluconic acid, either in its free form or in the form of a ferric salt. The complexes may be modified by mixing the reactants and adjusting the pH to 5-6 and then adding natural or depolymerized inulin to the reaction mixture and readjusting the pH to a value of 7 to 8 to give an inulin modified complex. Pharmaceutical compositions contain the above novel iron (III) complexes in aqueous solution with an iron content of 5-100 mg./ml. of solution. The solution may contain a resorption retarding agent such as polyvinyl pyrrolidone. The solutions may be produced in ampoules for parenteral administration.
Participants undergo standard of care smoking cessation intervention as in Group I and attend a health feedback counseling session at baseline. Participants also receive access to a smoking cessation hotline telephone number and supportive text messages daily for 12 weeks.
Patients had schizophrenia and fulfilled the criteria including having a score of 4 (moderate) or greater on any of the 7 items of the Positive and Negative Syndrome Scale (PANSS) Positive Symptom Subscale and needed to switch from previous antipsychotics due to insufficient efficacy or insufficient tolerability (N=61). They will receive the intervention of administration of quetiapine XR.
Participants will be offered services from a certified recovery specialist (i.e., the Peer Recovery Support program). This will entail a CRS meeting one-on-one with the patient at regular intervals (e.g., weekly) to provide support to the participant for a 6-month period. CRS services are patient-centered and driven by a patient's own recovery goals, thus the frequency, timing, duration, modality (in-person, phone), and location of meetings (in the clinic or in a community setting such as a coffeeshop) are flexible and determined collaboratively by the CRS and patient.
The aim of our study is to determine if a goal directed program improves weight loss outcomes after sleeve gastrectomy. Bariatric patients are managed by a multidisciplinary team comprising of bariatric surgeons, dieticians, physiotherapists, and physicians. In the conventional weight loss program, patients were only given their ideal weight to strive toward after surgery. Previous patients undergoing bariatric surgery in the standard program often enquired about the expected excessive weight loss targets after bariatric surgery. This patient driven need led to the development of the goal directed weight loss program. This modified program involves a component of behavioural intervention. Bariatric patients in this modified program will be counselled prior to LSG and EWL targets will be set for patients to achieve at fixed intervals post LSG. These targets are charted on a graph, with the patient's actual weight charted on the same graph at each clinic consultation, providing a strong visual aid to counseling and motivation.

The aim of the study is to recruit 120 patients undergoing laparoscopic sleeve gastrectomy. These patients will be randomized to either the goal directed program or a standard program. Patient demographics, preoperative weight, and post operative weights at 3, 6, 9, 12, 18 and 24 months post laparoscopic sleeve gastrectomy will be collected. Univariate and multivariate analyses will be performed between each group with excess weight loss being the primary endpoint.

Such a trial would allow evaluation to know if the effort spent in implementing a goal directed weight loss program translates to improved weight loss outcomes in bariatric surgery patients. There are no significant risks involved in implementing such a program for our patients. This is based on a retrospective review of patients who have undergone the goal directed program in NUH. If such a program is shown to improve weight loss outcomes post surgery, it could potentially be adopted by bariatric centers worldwide. If the goal directed program is shown to have no bearing on weight loss outcomes, the extra efforts by the bariatric team into implementing such a program could be better directed to other endeavours.
Electrolyte imbalance and acid–base balance abnormalities, e.g., hypocalcemia, metabolic alkalosis, etc. may occur in the event of an overdose. Stop administration promptly (see WARNINGS AND PRECAUTIONS). 

In patients with impaired citrate metabolism, e.g., liver failure, circulatory shock etc, overdosage with REGIOCIT solution may be manifested as citrate accumulation, metabolic acidosis, systemic total hypercalcemia and ionized hypocalcemia along with increased total calcium/ionized calcium ratio (see CONTRAINDICATIONS, and WARNINGS AND PRECAUTIONS). 

Careful calcium supplementation can reverse the effects of an overdose. The risk can be minimized by close monitoring during treatment.
Early studies with ribavirin in patients with AIDS and AIDS related complex (ARC) have shown that ribavirin appears to inhibit the spread of the virus. Determination of how much and how often to give the drug will require further knowledge of the pharmacokinetics and toxicity of the drug in patients with AIDS or ARC and in chronic virus carriers who do not have symptoms.

Ribavirin is given to HIV-infected patients intravenously as a timed 30-min infusion at 1 of 5 single doses; 2 weeks later, the same doses are given orally in a single dose. Following at least 2 additional weeks, 6 patients are then given ribavirin at the lowest dose twice a day for 16 weeks. They are evaluated for tolerance and the next group is given a higher dose. Each successive group begins at 3-week intervals to receive doses that increase each day until the MTD is reached. Blood samples taken periodically during the treatment period and for 8 weeks after treatment is stopped are used to measure blood levels of ribavirin and to determine the effects of ribavirin on the HIV and immune system of the patients.
Oral cancer is notoriously painful. Activation of protease-activated receptor 2 (PAR2, encoded by F2RL1) by proteases in the cancer microenvironment is implicated in oral cancer pain. PAR2 is a G protein-coupled receptor (GPCR) expressed on neurons and cells in the cancer microenvironment. Sustained signaling of PAR2 from endosomes of neurons mediates sensitization and nociception. We focused on the differential contribution of PAR2 on oral cancer cells and neurons to oral cancer pain and whether encapsulation of a PAR2 inhibitor, AZ3451 in nanoparticles (NP) more effectively reverses PAR2 activation. We report that F2RL1 was overexpressed in human oral cancers and cancer cell lines. Deletion of F2RL1 on cancer cells reduced cancer-associated mechanical allodynia. A third-generation polyamidoamine dendrimer, functionalized with cholesterol was self-assembled into NPs encapsulating AZ3451. NP encapsulated AZ3451 (PAMAM-Chol-AZ NPs) more effectively reversed activation of PAR2 at the plasma membrane and early endosomes than free drug. The PAMAM-Chol-AZ NPs showed greater efficacy in reversing nociception than free drug, with respect to both level and duration, in three preclinical mouse models of oral cancer pain. The antinociceptive efficacy was confirmed with an operant orofacial assay. Genetic deletion of F2RL1 on cancer cells or F2rl1 on neurons each partially reversed mechanical cancer allodynia. The remaining nociception could be effectively reversed by PAMAM-Chol-AZ NPs. These findings suggest that PAR2 on oral cancer cells and neurons contribute to oral cancer nociception and NPs loaded with a PAR2 antagonist provide increased antinociception and improved oral function compared to free drug.
PURPOSE: A method for suppressing bone metastasis using a specific antibody of CXCL10 is provided to suppress the function of CXCL10. CONSTITUTION: A method for suppressing bone metastasis of cancer cells is performed using a CXCL10-specific antibody. The CXCL10-specific antibody contains an amino acid sequence of sequence number 9. A pharmaceutical composition for preventing or treating metastatic cancer contains the CXCL10-specific antibody and pharmaceutically acceptable carrier or excipient. The CXCL10-specific antibody is derived from human, mammal, and poultry. The pharmaceutical composition contains CXCL10-specific polyclonal antibody. A kit for diagnosing bone metastasis of cancer cells contains CXCL10 and detectable label.
UNLABELLED: Rathke's cleft cysts (RCC) are a common type of lesion found in the sellar or suprasellar area. They are usually monitored clinically, but in some cases, surgery may be required. However, their natural progression is not yet well understood, and the outcomes of surgery are uncertain. The objective of this study is to evaluate the natural history of Rathke's cleft cysts in patients who are clinically monitored without treatment, and to determine the outcomes of surgery and the incidence of recurrences over time.
DESIGN AND PATIENTS: National multicentric study of patients diagnosed of Rathke's cleft cyst (RCC- Spain) from 2000 onwards and followed in 15 tertiary centers of Spain. A total of 177 patients diagnosed of RCC followed for 67.3 months (6-215) and 88 patients who underwent surgery, (81 patients underwent immediate surgery after diagnosis and 7 later for subsequent growth) followed for 68.8 months (3-235).
RESULTS: The cyst size remained stable or decreased in 73.5% (133) of the patients. Only 44 patients (24.3%) experienced a cyst increase and 9 of them (5.1%) experienced an increase greater than 3 mm. In most of the patients who underwent surgery headaches and visual alterations improved, recurrence was observed in 8 (9.1%) after a median time of 96 months, and no predictors of recurrence were discovered.
CONCLUSIONS: Rathke's cleft cysts without initial compressive symptoms have a low probability of growth, so conservative management is recommended. Patients who undergo transsphenoidal surgery experience rapid clinical improvement, and recurrences are infrequent. However, they can occur after a long period of time, although no predictors of recurrence have been identified.
This technology relates to an information processing device and method, as well as to a program, making it possible to obtain higher-probability information pertaining to taking medicines. An extraction unit extracts a prescription date and the number of prescription days for prescription drugs from medical prescription information recorded in a recording unit. When, among the prescription drugs, there are prescription drugs that have the same prescription date but a different number of prescription days, an operation unit performs division on the basis of the numbers of prescription days. When the result of the division satisfies a specific condition, the operation unit regards the prescription drug as a persistent-effect drug. A medicine-taking-schedule-generation unit regards the number of prescription days of the sustained-action drug as the number of prescription days of the other prescription drug that was prescribed on the same day is this sustained-action drug; and generates, from this number of prescription days and prescription date, medicine-taking schedule information indicating the medicine-taking schedule of the sustained-action drug. This technology can be applied to an information processing device.
In clinical trials, generally mild and transient burning and stinging followed application with ELIMITE® (permethrin) 5% Cream in 10% of patients and was associated with the severity of infestation. Pruritus was reported in 7% of patients at various times post-application. Erythema, numbness, tingling, and rash were reported in 1 to 2% or less of patients (see PRECAUTIONS: General). Other adverse events reported since marketing ELIMITE® (permethrin) 5% Cream include: headache, fever, dizziness, abdominal pain, diarrhea and nausea and/or vomiting. Although extremely uncommon and not expected when used as directed (see DOSAGE AND ADMINISTRATION), rare occurrences of seizure have been reported. None have been medically confirmed as associated with ELIMITE® treatment.